VEGFA and colorectal cancer: Using the NHIRD, the TCR, and Taiwan’s National Death Index, we enrolled 189,708 patients with newly diagnosed advanced colorectal cancer from 2009 to 2016 and assessed the relationship between anti-VEGF therapy and the risk of thromboembolic events and MACEs through 1:1 age, sex-, clinical stage, and diagnosis date matching and propensity score matching.